Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;49(12):1268-1277.
doi: 10.1111/1346-8138.16570. Epub 2022 Sep 12.

Cohort study of subclinical sensitization against galactose-α-1,3-galactose in Japan: Prevalence and regional variations

Yusei Nakagawa  1 , Yuko Chinuki  1 , Ryohei Ogino  1   2 , Kenshi Yamasaki  3 , Setsuya Aiba  3 , Tsukasa Ugajin  4 , Hiroo Yokozeki  4 , Kaoru Kitamura  5 , Eishin Morita  1
Affiliations

Cohort study of subclinical sensitization against galactose-α-1,3-galactose in Japan: Prevalence and regional variations

Yusei Nakagawa et al. J Dermatol. 2022 Dec.

Erratum in

Abstract

Sensitization to galactose-α-1,3-galactose (α-Gal) leads to the development of α-Gal syndrome, which includes red meat allergy and cetuximab-induced anaphylaxis. Since tick bites represent the main cause of α-Gal sensitization, it was speculated that sensitization to α-Gal occurs throughout Japan. However, few cohort studies have investigated α-Gal sensitization in Japan. Therefore, we aimed to elucidate the subclinical sensitization rate to α-Gal in Japan. Sera were obtained from 300 participants without food or cetuximab allergy at Shimane University Hospital (Shimane prefecture), Tokyo Medical and Dental University Hospital (Tokyo metropolis), and Tohoku University Hospital (Miyagi prefecture). ImmunoCAP-bovine thyroglobulin (BTG), ImmunoCAP-beef, and IgE immunoblotting with cetuximab were performed to detect α-Gal-specific IgE. Clinical information was collected from participants using a questionnaire. The overall positivity rate of ImmunoCAP-BTG was 4.0% without significant inter-institute differences, whereas that for ImmunoCAP-beef was 9.7% with a significant inter-institute difference. Tokyo Medical and Dental University Hospital (19.0%) had the highest positivity rate. The positivity rate based on cetuximab IgE immunoblotting was 2.7%, without any significant inter-institute differences. The overall positivity rate for both ImmunoCAP-BTG and cetuximab immunoblotting was 2.0%, with a significant inter-institute difference; 5.0% of Shimane University Hospital was the highest. Two cases showed sensitization against the non-α-Gal epitope of cetuximab. The overall positivity rate for both ImmunoCAP-beef and cetuximab immunoblotting was 1.3%, without significant inter-institute differences. Male sex was associated with positive beef-specific IgE. The prevalence of subclinical sensitization to α-Gal is estimated at 2.0%-4.0% in Japan and may be higher in rural areas, supporting an association between tick bites and α-Gal sensitization. In contrast, the prevalence of subclinical sensitization to beef is 9.7% in Japan and is highest in Tokyo Metropolis, suggesting the presence of another IgE-binding epitope apart from α-Gal and another sensitization route in the sensitization to beef IgE.

Keywords: beef; cetuximab; galactose-α-1,3-galactose; red meat allergy; tick bites.

PubMed Disclaimer

Similar articles

See all similar articles

References

REFERENCES

    1. Commins SP, Satinover SM, Hosen J, Mozena J, Borish L, Lewis BD, et al. Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-alpha-1,3-galactose. J Allergy Clin Immunol. 2009;123:426-33.
    1. Araujo RN, Franco PF, Rodrigues H, Santos LCB, McKay CS, Sanhueza CA, et al. Amblyomma sculptum tick saliva: α-gal identification, antibody response and possible association with red meat allergy in Brazil. Int J Parasitol. 2016;46:213-20.
    1. Cabezas-Cruz A, Hodzic A, Roman-Carrasco P, Mateos-Hernandez L, Duscher GG, Sinha DK, et al. Environmental and molecular drivers of the α-gal syndrome. Front Immunology. 2019;10:1210.
    1. Platts-Mills TAE, Li RC, Keshavarz B, Smith AR, Wilson JM. Diagnosis and management of patients with the α-gal syndrome. J Allergy Clin Immunol Pract. 2020;8:15-23.e1.
    1. Roman-Carrasco P, Hemmer W, Cabezas-Cruz A, Hodzic A, de la Fuenta J, Swoboda I. The α-gal syndrome and potential mechanisms. Front Allergy. 2021;2:783279.

Supplementary concepts

LinkOut - more resources